Multiple Myeloma Stem Cells and Drug Resistance in Myeloma Management
September 27, 2019
Upcoming / RECENT Talks

Multiple Myeloma Stem Cells and Drug Resistance in Myeloma Management

with Dr. William Matsui 
Sept 30, 2019, 11 AM ET
RSVP
Multiple myeloma is a heterogenous plasma cell disorder that contains a small fraction of clonogenic stem cells, just like many other cancers. Although the exact nature and biological properties of these cells remain elusive, multiple myeloma stem cells (MMSCs) have pronounced drug resistance and are believed to be the root cause of failure of many myeloma management therapies. We are talking to Dr William Matsui of LIVESTRONG Cancer Institutes to learn about the latest research on multiple myeloma stem cells and their role in novel drug development to treat multiple myeloma.
Panelists
Dr. William Matsui
Gary Petersen
Cynthia Chmielewski
Jack Aiello
Shweta Mishra 
Sept 4, 2019, 3 PM ET
LISTEN
Recently, the FDA approved a new cancer drug called Selinexor. This drug has been found to be successful in treating multiple myeloma in patients who have exhausted all other existing treatment options. Selinexor works on a different mechanism compared to other drugs. It enters a cell and targets mechanisms that move molecules into and out of the cell. We are talking to Dr. Dan Vogl, who lead the Phase II studies on Selinexor, on how the drug works, how it should be used, potential side effects and who should consider using it.






Panelists
Dr. Dan T Vogl
Gary Petersen
Jack Aiello
Cynthia Chmielewski
Priya Menon 
Sept 3, 2019, 2 PM ET
LISTEN
Nearly all patients with multiple myeloma first develop one of its precursor conditions. People with these conditions do not have any symptoms, and they are told to watch and wait to see if they develop multiple myeloma. Currently, there are no treatments that prevent the progression of myeloma precursor conditions. To overcome this, researchers need to understand changes happening at the molecular level and identify potential targets for treatment. Dr. Irene Ghobrial of Dana Farber Cancer Institute is talking to us about the new PROMISE study, the biggest myeloma screening study ever run to help prevent myeloma before it begins and share how you can join the study and help in research. 

 
Panelists
Dr. Irene Ghobrial
Tiffany H Williams
Misty Callahan
Dana Holmes
Priya Menon
For any of the talks dial-in to 718-664-6574 to participate and ask a question LIVE On-Air! Only 50 callers permitted at one time so HURRY!
Our Picks